RARG
Retinoic acid receptor gamma
As of the edition of 20 October 2026, RARG (retinoic acid receptor gamma, UniProt P13631) has 10 drugs tested at it and 19 companies on the list, 0 on route A and 7 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P13631
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 11
- Disease areas
- Cancer; Skin and connective tissue; Blood and lymph; Immune system; Urinary and reproductive; Infections; Lungs and airways; Digestive system
- Registered trials of its drugs
- 435
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 8 |
| Withdrawn from market | 1 |
| Status not established | 1 |
| Total | 10 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tretinoin | Marketed | Phase 4 | none listed |
| Isotretinoin | Marketed | Phase 4 | none listed |
| Adapalene | Marketed | Phase 4 | none listed |
| Tazarotene | Marketed | Phase 4 | none listed |
| Acitretin | Marketed | Phase 4 | none listed |
| Alitretinoin | Marketed | Phase 3 | none listed |
| Trifarotene | Marketed | Phase 4 | Ends 2031 |
| Palovarotene | Marketed | Phase 3 | Ends 2030 |
| TMB-001 | Status not established | Phase 3 | none listed |
| Etretinate | Withdrawn from market | No phase stated | none listed |
10 of 10 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 7 |
| Engaged | 7 |
| Undetermined | 5 |
| Total on the list | 19 |
The other 16 companies at RARG
In the product19 companies in all; 16 are not named here, and no score is.
See the 19 companies at RARG, ranked, with the facts behind eachRequest access. Nothing is shown until you do.